reSee.it - Related Video Feed

Gene injections, also known as vaccines, aim to stimulate adaptive immunity and neutralizing antibodies to eliminate the virus. However, the Pfizer and Moderna vaccines have shown negative efficacy, with vaccinated individuals getting infected and reinfected. This leads to the emergence of more infectious variants. Continuing the current vaccine rollout will prolong the pandemic, as new variants will keep emerging. Vaccinating during a pandemic with high infectious pressure is a catastrophic mistake. These vaccines cannot and will not work.

"The mRNA vaccines, you know, from COVID don't work against upper respiratory infections." "There are two problems with them." "One is they target a single protein, which drives what what's called an antigenic shift." "If it drives the virus to mutate, and it actually can prolong the pandemic." "We saw that during COVID, people took shots, mRNA shots for the original COVID variant and immediately, mutated into the Omicron virus to which the vaccine was ineffective, and that's what it does." "And the other issue is, that it the way that distributes in the body, the way that it migrates in the body, there's no control over and no predictability." "So it goes to every organ." "It turns your body into a an antigen factory where you're manufacturing antigens, and different people need different loads of antigens." "And we've seen now these epidemics of myocarditis and pericarditis, particularly in kids."

Robert F. Kennedy Jr. states that HHS, via BARDA, is canceling 22 mRNA vaccine development investments, mostly for flu and COVID. He claims mRNA vaccines don't perform well against viruses infecting the upper respiratory tract because mRNA only codes for a small part of viral proteins, and one mutation can make the vaccine ineffective. Kennedy alleges this drives antigenic shift, where vaccines encourage new mutations, prolonging pandemics as viruses mutate to escape the vaccine's protection. He asserts that HHS, after reviewing science and consulting experts at NIH and FDA, determined mRNA technology poses more risk than benefits for respiratory viruses. According to Kennedy, BARDA is terminating contracts totaling just under $500,000,000 and prioritizing safer, broader vaccine strategies like whole virus vaccines. He clarifies that HHS supports safe, effective vaccines but is moving beyond mRNA's limitations for respiratory viruses.

Secretary Kennedy has achieved a major victory, effectively silencing many critics. While not a complete ban on mRNA, the government, through BARDA, will cease investing in these technologies. Additionally, their global health investment corporation partner is advised to halt all equity investments in modified RNA technologies. The expectation is that without government funding, these technologies will diminish. This development is considered a bombshell with worldwide repercussions.

There is a new mRNA COVID-19 vaccine, but there is no evidence to support its effectiveness or safety in human trials. Additionally, several studies from different countries suggest that these vaccines may actually increase the risk of contracting COVID-19 over time. This is concerning and not a typical outcome.

The speaker believes that halting mRNA vaccine research and development at BARDA is a tragic, non-science-based mistake. They state that mRNA vaccines saved lives, citing estimates that in 2021, unvaccinated individuals were 12 times more likely to be hospitalized and die, and in 2022, six times more likely. The speaker, a member of the FDA vaccine advisory committee, notes initial concerns about potential serious side effects when the vaccine was rolled out to millions, but these did not materialize. While the vaccine can cause rare myocarditis, it is transient and self-resolving, unlike myocarditis caused by the virus itself, which can lead to hospitalization and death. The speaker emphasizes the technology's potential beyond COVID-19, including applications for cancer and gene therapy.

mRNA vaccines code for a small part of viral proteins, usually a single antigen. A single mutation can make the vaccine ineffective. This drives antigenic shift, where the vaccine encourages new mutations, prolonging pandemics as the virus mutates to escape the vaccine's protection. Millions caught the Omicron variant despite vaccination because a single mutation can render mRNA vaccines ineffective. The same risk applies to the flu.

Robert F. Kennedy Jr., as HHS Secretary, states that BARDA is canceling 22 mRNA vaccine development investments, primarily for flu and COVID. He claims mRNA vaccines don't perform well against upper respiratory viruses because they only code for a small part of viral proteins, and a single mutation can make them ineffective. Kennedy alleges this drives antigenic shift, where vaccines encourage new mutations, potentially prolonging pandemics. He asserts that millions contracted Omicron despite vaccination, illustrating this risk. HHS, after consulting NIH and FDA experts, has determined mRNA technology poses more risk than benefit for respiratory viruses. The canceled contracts total just under $500 million. HHS will prioritize safer, broader vaccine strategies like whole virus vaccines and novel platforms that don't collapse when viruses mutate. Kennedy states HHS supports safe, effective vaccines but is moving beyond mRNA limitations for respiratory viruses.

The speaker is questioned about the Health Secretary pulling funding for mRNA vaccine research, claiming the risks outweigh the benefits, putting him at odds with the medical community. The speaker responds that Operation Warp Speed was considered incredible, regardless of political affiliation, citing its efficiency and distribution. While acknowledging that Warp Speed was "a long time ago," the speaker states that they are "on to other things" and are looking for answers to other sicknesses and diseases. They mention upcoming meetings to determine the next steps.

Secretary Kennedy has achieved a significant victory, effectively silencing many critics. While not a ban on mRNA, the government, through BARDA, will cease investing in these technologies. Additionally, their global health investment corporation partner is advised to halt all equity investments in modified RNA technologies. The expectation is that without funding, these technologies will diminish. This development is considered a bombshell with worldwide repercussions.

There are three basic vaccine technologies, none of which are safe. The three technologies are live attenuated vaccines, killed-virus/virus-fragment vaccines with adjuvants, and mRNA vaccines. Live attenuated vaccines can cause one person a tiny mild infection while another may suffer a more serious one, and they can evolve and spread; though not supposed to be contagious, they can produce contagious effects. For example, the polio vaccine, live attenuated, has created many polio cases, an intolerable downside. The killed-virus approach doesn't reliably stimulate immunity unless an adjuvant is used; adjuvants are nonspecific and can trigger widespread immune activation. The mRNA approach is unsafe because it moves haphazardly through the body, causing cells to produce foreign antigens, which the immune system may attack as virally infected, potentially deadly in the heart, and tissue destruction elsewhere. In sum, three technologies, none fundamentally safe, with severe downsides.

Robert F. Kennedy Jr., as HHS secretary, explains that BARDA is canceling 22 mRNA vaccine development investments, primarily for flu and COVID. He claims mRNA vaccines don't perform well against upper respiratory viruses because they only code for a small part of viral proteins, and a single mutation can make them ineffective. This drives antigenic shift, paradoxically encouraging new mutations and prolonging pandemics. HHS has determined that mRNA technology poses more risk than benefits for these viruses. The canceled contracts total just under $500 million. HHS will prioritize safer, broader vaccine strategies like whole virus vaccines and novel platforms that don't collapse when viruses mutate. HHS supports safe, effective vaccines and is moving beyond the limitations of mRNA for respiratory viruses.

"this is a massive win for Secretary Kennedy and basically a silencing of many of the critics." "It's not a ban on mRNA like many people would like to see." "However, it is the wind down of the government investing through BARDA in these technologies." "and their global health investment corporation partner is advised to stop all equity investments in modified RNA technologies." "So follow the money." "When the money isn't there, these are going to fizzle." "This is a bombshell." "The repercussions are going to be felt worldwide." "There will be backlash." "It's not for human use." "This de investment in these 22 projects, it's just the beginning."

Robert F. Kennedy Jr. states that HHS, via BARDA, is canceling 22 mRNA vaccine development investments, mostly for flu and COVID. He claims mRNA vaccines don't perform well against viruses infecting the upper respiratory tract because mRNA only codes for a small part of viral proteins, and one mutation can make the vaccine ineffective. Kennedy alleges this drives antigenic shift, where vaccines encourage mutations and prolong pandemics as viruses mutate to escape the vaccine's protection. HHS has determined that mRNA technology poses more risk than benefits for these respiratory viruses. The canceled contracts total just under $500,000,000. HHS is prioritizing safer, broader vaccine strategies like whole virus vaccines and novel platforms that don't collapse when viruses mutate. HHS supports safe, effective vaccines but is moving beyond the limitations of mRNA for respiratory viruses.

Robert F. Kennedy Jr.: Hi, it's Robert F. Kennedy Jr. here, your HHS secretary. At HHS, we have a division called the Biomedical Advanced Research and Development Authority, or BARDA. BARDA drives some of our most advanced scientific research. It funds developments of vaccines, drugs, diagnostics, and other tools to fight emerging diseases and national health threats. Over the past few weeks, BARDA reviewed 22 mRNA vaccine development investments and began canceling them. Let me explain why. Most of these shots are for flu or COVID, but as the pandemic showed us, mRNA vaccines don't perform well against viruses that infect the upper respiratory tract. Here's the problem: mRNA only codes for a small part of the viral proteins, usually a single antigen. One mutation and the vaccine becomes ineffective. This dynamic drives a phenomena called antigenic shift, meaning that the vaccine paradoxically encourages new mutations and can actually prolong pandemics as the virus constantly mutates to escape the protective effects of the vaccine. Millions of people, maybe even you or someone you know, caught the omicron variant despite being vaccinated. That's because a single mutation can make mRNA vaccines ineffective. The same risk applies to flu. After reviewing the science and consulting top experts at NIH and FDA, HHS has determined that mRNA technology poses more risk than benefits for these respiratory viruses. That's why after extensive review, BARDA has begun the process of terminating these 22 contracts totaling just under $500,000,000 To replace the troubled mRNA programs, we're prioritizing the development of the safer, broader vaccine strategies, like whole virus vaccines and novel platforms that don't collapse when viruses mutate. Let me be absolutely clear: HHS supports safe, effective vaccines for every American who wants them. That's why we're moving beyond the limitations of mRNA for respiratory viruses and investing in better solutions. Thank you. Produced by the U. S. Department of Health and Human Services.

Robert F. Kennedy Jr. states that HHS, via BARDA, is canceling 22 mRNA vaccine development investments, mostly for flu and COVID, because mRNA vaccines don't perform well against upper respiratory viruses. mRNA only codes for a small part of viral proteins, and one mutation can make the vaccine ineffective, driving antigenic shift, which encourages new mutations and prolongs pandemics. Millions caught Omicron despite being vaccinated, demonstrating this. HHS determined mRNA technology poses more risk than benefit for respiratory viruses after consulting experts at NIH and FDA. BARDA is terminating contracts totaling just under $500 million. HHS is prioritizing safer, broader vaccine strategies like whole virus vaccines and novel platforms that don't collapse when viruses mutate. HHS supports safe, effective vaccines but is moving beyond the limitations of mRNA for respiratory viruses.

The mRNA platform is effective but has a flaw: it can cause autoimmune disorders by producing foreign proteins in cells. The challenge is to target only specific cells and avoid damage to vital organs. The pandemic allowed the emergency use authorization of mRNA vaccines, bypassing safety measures. However, a large portion of the population has already accepted this technology. To address the issue, a solution could be to replace the spike protein with a different protein that doesn't have flaws. But if the problem lies in any foreign protein transcribed by cells, the immune system may still target vital organs.

- The mRNA vaccines, you know, from COVID don't work against upper respiratory infections. - There are two problems with them. - One is they target a single protein, which drives what what's called an antigenic shift. - If it drives the virus to mutate, and it actually can prolong the pandemic. - And we saw that during COVID, people took shots, mRNA shots for the original COVID variant and immediately, mutated into the Omicron virus to which the vaccine was ineffective, and that's what it does. - And the other issue is, that it the way that distributes in the body, the way that it migrates in the body, there's no control over and no predictability. - So it goes to every organ.

The US Health Department intends to cancel contracts and cut funding for some vaccine development projects, including those targeting COVID-19. Health Secretary Robert F. Kennedy Jr. announced that $500 million in funding would be halted for 22 projects, many led by major drug makers like Pfizer and Moderna. These projects use mRNA technology. While mRNA vaccines are credited with slowing the 2020 coronavirus pandemic, Kennedy stated he wants the department to invest in "better solutions," but did not elaborate on what those solutions would be. The Department of Health and Human Services is pulling the funding and Kennedy is calling on the department to move away from mRNA vaccines.

The US Health Department intends to cancel contracts and cut funding for some vaccine development projects, including those targeting COVID-19. Health Secretary Robert F. Kennedy Jr. announced the halt of $500 million in funding for 22 projects, many led by major drug makers like Pfizer and Moderna. These projects utilize mRNA technology. While mRNA vaccines are credited with slowing the 2020 coronavirus pandemic, Kennedy stated he wants the department to invest in "better solutions," though he did not specify what those solutions would be.

US Health Secretary Robert F. Kennedy has blocked $500 million in funding for respiratory disease vaccine research, canceling over 20 government contracts for mRNA jabs. Kennedy, a long-time vaccine skeptic, stated his department concluded the vaccines pose more risk than protection against respiratory illness. Professor Jonathan Ball, a Molecular Virology expert, responded by calling the move an example of misinformation and anti-science. He stated that mRNA vaccines have been incredibly effective, helped bring the COVID pandemic under control, and offer great hope for other infectious diseases.

Robert F. Kennedy Jr., as HHS Secretary, announces the cancellation of 22 BARDA mRNA vaccine development investments, primarily for flu and COVID. HHS determined mRNA vaccines pose more risk than benefit for respiratory viruses because they only code for a small part of viral proteins, and a single mutation can render them ineffective. This can drive antigenic shift, prolonging pandemics as viruses mutate to escape the vaccine's effects. Millions contracted Omicron despite vaccination, illustrating this risk. HHS will prioritize safer, broader vaccine strategies like whole virus vaccines and novel platforms that don't collapse when viruses mutate. The 22 contracts totaled just under $500,000,000. HHS supports safe, effective vaccines and is moving beyond mRNA limitations for respiratory viruses.

MRNA vaccines were hailed as medical breakthroughs in the fight against COVID. Now the US Department of Health and Human Services is slashing a half billion dollars in government funding from mRNA vaccine development. The current vaccines are not infection blocking. When new variants come up, you lose protection, and they have very short duration. There was never a vaccine made with mRNA. Lipid nanoparticles go everywhere in the body, to the brain, to the bone marrow, to the liver, to the spleen, most importantly to the reproductive organs. I regret it every single day that I walked into my local pharmacy to get that shot in my arm. The spike protein directly causes blood clotting and is found in the middle of large blood clots. This vaccine, the mRNA vaccine, has probably saved about three million lives.

- "After reviewing the science and consulting top experts at NIH and FDA, HHS has determined that mRNA technology poses more risk than benefits for these respiratory viruses." - "BARDA has begun the process of terminating these 22 contracts totaling just under $500,000,000 To replace the troubled mRNA programs, we're prioritizing the development of safer, broader vaccine strategies, like whole virus vaccines and novel platforms that don't collapse when viruses mutate." - "I'm still waiting for Robert Kennedy Jr. To say that we're going to wipe out mandates and everyone will have a choice, but this is a great step in the right direction." - "Half a billion dollars, 22 projects in the pipeline for mRNA vaccine technology." - "KFF Foundation did a survey on really what Americans are still going to want this vaccine going into the fall, the COVID vaccine."

Secretary Kennedy has achieved a significant victory, effectively silencing many critics. While not a ban on mRNA, the government, through BARDA, will cease investing in these technologies. Additionally, their global health investment corporation partner is advised to halt all equity investments in modified RNA technologies. The expectation is that without funding, these technologies will diminish. This development is considered a bombshell with worldwide repercussions.